SCHEMBL22014925

SCHEMBL22014925

CC(C)(O)c1ncc(C(N)=O)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FFAR2 O15552 1/20 0.35
F2 P00734 1/20 0.34
PIM1 P11309 2/20 0.34
PIM2 Q9P1W9 2/20 0.34
GSK3B P49841 2/20 0.33
SCD O00767 2/20 0.33
KDR P35968 2/20 0.33
DAPK3 O43293 2/20 0.33
CSNK1A1 P48729 2/20 0.33
LIMK1 P53667 2/20 0.33
ROCK1 Q13464 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
DYRK1B Q9Y463 2/20 0.33
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18183949 0.87 BTK (0.39) HCAR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2514314 0.83 HCAR2 (0.55) HCAR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2146812 0.79 SCD (0.42) ALDH1A1F2PIM1GSK3BSCD
SCHEMBL12503941 0.76 SCD (0.38) HCAR2FFAR2F2PIM1GSK3B
SCHEMBL20698957 0.74 SMN1; SMN2 (0.39) SMN1; SMN2F2
SCHEMBL22598029 0.73 HCAR2 (0.35) HCAR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL328096 0.72
SCHEMBL20692099 0.72 NOS1 (0.32)
SCHEMBL13962017 0.72 ALDH1A1 (0.42) HCAR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3001292 0.71 F2 (0.41) HCAR2SMN1; SMN2FFAR2F2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658538-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-04-19 EP disclosed
WO-2020102574-A1 THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed
CN-101541801-A Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL (JP) 2009-09-23 CN disclosed